NONOF Company Profile and Key Details

Average 10-day trading volume of 8.70 thousand shares is below the 3-month average of 173.58 thousand, indicating normal recent market interest.

Novo Nordisk A/S earnings surprise history is a mixed track record. The quarter that ended May 06, 2026, missed forecasts by 10.27%. The prior quarter beat by 2.82%. Over the last six quarters, Apple has recorded several small beats. These include 8.59% in May 07, 2025.

Novo Nordisk A/S (OTC:NONOF) closed at $43.40 USD, losing -$0.61 (-1.39%) from the previous close of $44.01. The stock is currently mid-range between its 52-week high and low $34.00 and $75.25. With a market capitalization of about $192.80 billion, Novo Nordisk A/S is classified as a large-cap and shows lower-than-market volatility (beta ~0.35). Key stats such as the average daily volume over the past year has been around 172.00 thousand shares, volume is running light vs its 52-week average. Headquartered in Bagsvaerd, None, Novo Nordisk A/S operates in the Healthcare sector and the Drug Manufacturers - General industry. Led by CEO Maziar Mike Doustdar, the company employs approximately 77,406 people and listed since May 07, 2010. Novo Nordisk A/S operates as a prominent global pharmaceutical firm, dedicated to the discovery, development, production, and distribution of a wide array of medicinal products.

Novo Nordisk A/S last paid a dividend of 1.8 per share, this equals a trailing yield of roughly 7.24%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $81.80. This means the shares are trading below this model’s fair value.

Valuation shows Novo Nordisk A/S trading at a premium to the broader market with a P/E of 10.3.

Our AI price prediction model suggests that Novo Nordisk A/S stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Novo Nordisk A/S trades at a P/E ratio of 10.3, slightly below the S&P 500 average, with a price-to-sales ratio of 3.83 and a price-to-book ratio of 6.18 trading at moderately above to book value. The P/FCF stands at 21.56, also above market averages.